Clinical efficacy of NUCALA

NUCALA provides proven protection from flares1

72%

of patients had

ZERO flares vs

44% with placebo

Results are descriptive.

Primary endpoint results: Proportion of patients who experienced HES flare(s)* during the 32-week study or withdrew. NUCALA 28% vs placebo 56%, P=0.002.

*HES flare: Worsening of clinical signs/symptoms or increased eosinophils (on ≥2 occasions), resulting in an escalation/addition of oral corticosteroids (OCS) or cytotoxic or immunosuppressive therapy.

NUCALA increased time to first flare1

66%

reduction in

the risk of flare*

Secondary endpoint results: 66% lower risk of first HES flare during the 32-week study or withdrew. NUCALA vs placebo (HR: 0.34; 95% CI: 0.18, 0.67, P=0.002).

CI=confidence interval, HR=hazard ratio.

Patients taking NUCALA reported improvement in fatigue1

Improvement in fatigue was based on Brief Fatigue Inventory (BFI) Item 3, which asked patients to record their worst level of weariness/tiredness severity during the past 24 hours. BFI scale: 0=no fatigue to 10=as bad as you can imagine.1,2 Baseline median BFI Item 3 scores: NUCALA: 4.46; Placebo: 4.69.3

Median change from baseline in BFI Item 3 at Week 32 in 

“Worst level of fatigue in the past 24 hours”1

Median change from baseline in BFI Item 3 chart
Median change from baseline in BFI Item 3 chart

Secondary endpoint. 

An MCID has not been established in the BFI for HES. 

MCID=minimum clinically important difference.

NUCALA Autoinjector icon